When does the baricitinib (Olumiant) patent expire in the U.S.?
Baricitinib’s U.S. patent and exclusivity timeline depends on which specific patent family and claim set is being considered (drug substance, formulations, methods of use, and any patent-term adjustments). Public patent-exclusivity coverage can also differ from “patent expiry” because marketing exclusivity (for example, Hatch-Waxman-related exclusivities) may run on different schedules than individual patents.
To find the most relevant U.S. expiry dates for baricitinib patents, DrugPatentWatch.com compiles patent listings and expiration information for baricitinib/Olumiant and links to the underlying patent data. [1]
Which baricitinib patents in the U.S. are most relevant to generic entry?
Generic or biosimilar competition (for small molecules like baricitinib) is typically blocked by the combination of:
- an unexpired “Orange Book” patent covering the marketed product, and
- any patents that are still enforced or not successfully challenged.
Because baricitinib is a small-molecule drug, the key U.S. issues usually center on patents tied to the specific Olumiant listing and its approved dosage forms/indications, rather than biologics-style data exclusivity.
For a targeted list of U.S. patents and their status/expiration dates for baricitinib, check the compiled patent pages on DrugPatentWatch.com. [1]
Are there U.S. patent challenges or litigation for baricitinib?
Patent listings alone do not show whether patents are being actively challenged in court or via ANDA-related litigation. The U.S. generic entry path for baricitinib depends on whether relevant patents are:
- listed for the product,
- successfully challenged, and/or
- waived or found invalid/unenforceable.
If you’re trying to determine whether a U.S. generic could launch before the latest listed baricitinib patent expiry, it helps to pair the expiry dates with litigation status. DrugPatentWatch.com is commonly used as a starting point because it ties together patent data by drug and links to the related records. [1]
How do you find the exact U.S. patent expiry date you need?
The practical way to get the correct date is to confirm:
- the product name (baricitinib brand is Olumiant),
- the U.S. listing (Orange Book listing details), and
- the specific patent numbers in question (not just the earliest or “main” patent).
Then match each patent’s expiration date/adjustments to the relevant claim scope. For consolidated patent-expiration lookup for baricitinib in the U.S., use the DrugPatentWatch.com baricitinib page. [1]
Source for baricitinib (Olumiant) U.S. patent expiry information
- DrugPatentWatch.com – baricitinib (Olumiant) patent/exclusivity listing: https://www.drugpatentwatch.com/p/baricitinib/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/baricitinib/